CN115397429A - 急性髓性白血病或骨髓增生异常综合征治疗 - Google Patents

急性髓性白血病或骨髓增生异常综合征治疗 Download PDF

Info

Publication number
CN115397429A
CN115397429A CN202080095784.4A CN202080095784A CN115397429A CN 115397429 A CN115397429 A CN 115397429A CN 202080095784 A CN202080095784 A CN 202080095784A CN 115397429 A CN115397429 A CN 115397429A
Authority
CN
China
Prior art keywords
compound
lymphoma
leukemia
subject
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095784.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·R·布雷
J·M·玛森
G·弗莱彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CN115397429A publication Critical patent/CN115397429A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080095784.4A 2019-12-06 2020-12-04 急性髓性白血病或骨髓增生异常综合征治疗 Pending CN115397429A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944876P 2019-12-06 2019-12-06
US62/944,876 2019-12-06
PCT/CA2020/051668 WO2021108918A1 (en) 2019-12-06 2020-12-04 Treatment for acute myeloid leukemia or myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
CN115397429A true CN115397429A (zh) 2022-11-25

Family

ID=76221282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095784.4A Pending CN115397429A (zh) 2019-12-06 2020-12-04 急性髓性白血病或骨髓增生异常综合征治疗

Country Status (12)

Country Link
US (1) US12533357B2 (https=)
EP (1) EP4069246A4 (https=)
JP (1) JP2023505301A (https=)
KR (1) KR20220124177A (https=)
CN (1) CN115397429A (https=)
AU (1) AU2020396807A1 (https=)
BR (1) BR112022011052A2 (https=)
CA (1) CA3163796A1 (https=)
IL (1) IL293623A (https=)
MX (1) MX2022006910A (https=)
TW (1) TWI880995B (https=)
WO (1) WO2021108918A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
JP7717842B2 (ja) 2021-05-11 2025-08-04 オリック ファーマシューティカルズ，インク． ポロ様キナーゼ４阻害剤
US20250049787A1 (en) * 2021-12-22 2025-02-13 University Health Network Treatment for acute myeloid leukemia or lymphoma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764511A (zh) * 2013-10-04 2016-07-13 艾普托斯生物科学公司 用于治疗癌症的组合物和方法
WO2019046949A1 (en) * 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
SI2556071T1 (sl) * 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
ES2706066T3 (es) * 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
HUE043194T2 (hu) * 2013-10-18 2019-08-28 Univ Health Network PLK-4 inhibitor sója és kristályformái
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
JP6617208B2 (ja) 2017-03-31 2019-12-11 ノバルティス アーゲー 血液腫瘍におけるｈｄｍ２−ｐ５３相互作用阻害剤の用量およびレジメン
EP3720560A4 (en) * 2017-12-06 2022-01-05 Ludwig Institute for Cancer Research Ltd METHOD OF TREATMENT OF CANCER WITH PLK4 INHIBITORS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764511A (zh) * 2013-10-04 2016-07-13 艾普托斯生物科学公司 用于治疗癌症的组合物和方法
WO2019046949A1 (en) * 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YI ZHAO ET AL.: ""PLK4: a promising target for cancer therapy"", 《JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY》, vol. 145, pages 2413, XP036889889, DOI: 10.1007/s00432-019-02994-0 *
YI ZHAO ET AL.: ""Targeting Polo-like Kinase 4 for Therapeutic Benefit in the Patients with Diffuse Large B-Cell Lymphoma"", 《BLOOD》, vol. 134, 13 November 2019 (2019-11-13), pages 1 - 4 *

Also Published As

Publication number Publication date
US12533357B2 (en) 2026-01-27
WO2021108918A1 (en) 2021-06-10
AU2020396807A1 (en) 2022-07-21
CA3163796A1 (en) 2021-06-10
MX2022006910A (es) 2022-11-09
TWI880995B (zh) 2025-04-21
KR20220124177A (ko) 2022-09-13
BR112022011052A2 (pt) 2022-08-16
EP4069246A4 (en) 2023-12-06
EP4069246A1 (en) 2022-10-12
TW202134237A (zh) 2021-09-16
JP2023505301A (ja) 2023-02-08
IL293623A (en) 2022-08-01
US20230010772A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
CA2856646C (en) Combination treatment of cancer
EP2702054B1 (en) Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
US20120295864A1 (en) Method for treating acute myeloid leukemia
CN115397429A (zh) 急性髓性白血病或骨髓增生异常综合征治疗
AU2013402794A1 (en) Cancer treatment with combination of plinabulin and taxane
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
JP7242097B2 (ja) 免疫チェックポイント抑制剤を含む抗がん用組成物
JP2023529365A (ja) 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ
TWI849001B (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
EP4095137A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
CN115038447A (zh) 用于治疗癌症的组合疗法
CN117482092A (zh) [(4-羟基-1-甲基-7-苯氧基异喹啉-3-羰基)氨基]乙酸（罗沙司他）用于治疗化疗诱导的贫血（cia）
EA049792B1 (ru) Лечение острого миелоидного лейкоза или миелодиспластического синдрома
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
CN114761010B (zh) 喹唑啉衍生物或其盐的联用药物组合物及其用途
WO2025247377A1 (zh) 亚氨基砜类化合物治疗淋巴瘤的用途
HK40114211A (zh) [(4-羟基-1-甲基-7-苯氧基异喹啉-3-羰基)氨基]乙酸(罗沙司他)用於治疗化疗诱导的贫血(cia)
CN102872040B (zh) Gypensapogenin B在制备升高血小板的药物中的应用
HK40113623A (zh) [(4-羟基-1-甲基-7-苯氧基异喹啉-3-羰基)氨基]乙酸(罗沙司他)用於治疗化疗诱导的贫血(cia)
CN121285550A (zh) 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途
WO2025157254A1 (zh) 一种含有磺酰基的化合物的药物组合及其用途
NZ625611B2 (en) Combination treatment of cancer
HK1202253B (en) Combination treatment of cancer
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination